Is Bristol-Myers Squibb’s ImClone Takeover Bid A Preemptive Grab?
This article was originally published in The Pink Sheet Daily
Executive Summary
BMS takeover bid may be aimed at thwarting a spin-off, controlling potential Erbitux competition.
You may also be interested in...
Mystery Date: ImClone Rejects Bristol For Unnamed $70 Per Share Bidder
Much industry speculation suggests Icahn seeks higher bid from BMS, which initially offered $60 per share.
Mystery Date: ImClone Rejects Bristol For Unnamed $70 Per Share Bidder
Much industry speculation suggests Icahn seeks higher bid from BMS, which initially offered $60 per share.
PDL Deal Adds To BMS’ Chips In Multiple Myeloma
Phase I antibody represents novel, targeted approach in a busy space.